This editorial, by Janet Woodcock of FDA, discusses how the drug development enterprise will fit into the evolving CER enterprise (or vice versa). She suggests that the integration of research and practice offers the best opportunity for generating the data needed for evidence-based medicine and informing medical product development. Read more here. (Source: Journal of Comparative Effectiveness Research, 2(2), 95-97, 2013)
You are here: / How will CER intersect with the development and regulatory framework that currently exists?